Find comprehensive information on Uterine Leiomyosarcoma including diagnosis, treatment, and prognosis. This resource covers relevant medical coding (ICD-10, ICD-O), clinical documentation improvement, pathology, staging, and healthcare management of uterine leiomyosarcoma. Learn about symptoms, risk factors, and the latest research for this rare uterine cancer. Explore support resources for patients and healthcare professionals dealing with uterine LMS.
Also known as
Malignant neoplasm of body of uterus
Cancer specifically affecting the uterine body (corpus).
Malignant neoplasm of cervix uteri
Cancer involving the cervix, the lower part of the uterus.
Malignant neoplasm of other and unspecified female genital organs
Cancers of female genital organs not classified elsewhere.
Secondary malignant neoplasm of other specified sites
Metastatic cancer spread to specified sites, including the uterus.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis uterine leiomyosarcoma?
When to use each related code
| Description |
|---|
| Uterine Leiomyosarcoma |
| Uterine Leiomyoma |
| Endometrial Stromal Sarcoma |
Lack of pathology report confirming leiomyosarcoma diagnosis leading to inaccurate coding and potential claims denial.
Imprecise documentation of the primary site within the uterus (e.g., corpus, cervix) affecting accurate code assignment.
Incorrect or missing documentation of stage (I-IV) based on clinical findings impacting severity and reimbursement.
Q: What are the key diagnostic imaging features to look for when differentiating uterine leiomyosarcoma from benign uterine fibroids in a premenopausal patient?
A: Differentiating uterine leiomyosarcoma (ULMS) from benign uterine fibroids can be challenging, especially in premenopausal patients. While both may present with similar symptoms like pelvic pain and abnormal bleeding, certain imaging features can aid in the distinction. On ultrasound, ULMS often displays rapid growth, irregular margins, areas of necrosis, and increased vascularity compared to fibroids. MRI offers superior soft tissue contrast, and suspicious features include a heterogeneous appearance, ill-defined margins, and a non-uniform enhancement pattern after gadolinium administration. Necrosis, hemorrhage, and infiltration into surrounding structures are also highly suggestive of malignancy. However, biopsy remains the gold standard for definitive diagnosis. Consider implementing a multi-modal imaging approach incorporating both ultrasound and MRI for a comprehensive assessment when ULMS is suspected. Explore how incorporating standardized reporting templates can enhance diagnostic accuracy and communication in complex uterine cases.
Q: How should I approach the surgical management of suspected uterine leiomyosarcoma in a woman wishing to preserve fertility?
A: Surgical management of suspected uterine leiomyosarcoma in a fertility-preserving setting presents unique challenges. While complete surgical staging including hysterectomy and bilateral salpingo-oophorectomy is the standard treatment for ULMS, options for fertility preservation may be considered in select cases with early-stage disease confined to a single, small leiomyoma. Myomectomy can be performed, however, it carries a risk of tumor spillage and potential dissemination of malignant cells. Careful surgical technique including meticulous enucleation and minimizing uterine manipulation is crucial. Patients must be thoroughly counseled about the potential risks and benefits of this approach, including the risk of recurrence and the potential need for subsequent hysterectomy. Close surveillance with regular imaging and endometrial biopsies is essential post-myomectomy. Learn more about the latest research on fertility-sparing surgical techniques for uterine leiomyosarcoma and the role of neoadjuvant chemotherapy in these cases.
Patient presents with complaints consistent with uterine leiomyosarcoma symptoms, including abnormal uterine bleeding (menorrhagia, metrorrhagia, postmenopausal bleeding), pelvic pain or pressure, abdominal distension, and palpable abdominal mass. Differential diagnosis includes uterine fibroids, endometrial carcinoma, and other uterine malignancies. Physical examination revealed an enlarged uterus. Pelvic ultrasound demonstrated a heterogeneous uterine mass with features suspicious for leiomyosarcoma. Subsequent MRI of the pelvis with and without contrast confirmed the presence of a large, complex uterine mass, further raising suspicion for uterine leiomyosarcoma. Biopsy confirmed the diagnosis of uterine leiomyosarcoma, grade [insert grade]. Tumor markers, including lactate dehydrogenase (LDH), were evaluated. Staging workup, including CT scan of the chest, abdomen, and pelvis, is planned to assess for metastatic disease. The patient was counseled regarding treatment options, including total hysterectomy with bilateral salpingo-oophorectomy, lymphadenectomy, and possible adjuvant chemotherapy or radiation therapy. The risks and benefits of each treatment modality were discussed, and the patient will be scheduled for surgery. The patient's prognosis, based on tumor grade and stage, was also discussed. Follow-up care and surveillance will be arranged. ICD-10 code C54.1, uterine leiomyosarcoma, and appropriate CPT codes for the procedures performed will be documented. This documentation supports medical necessity for the diagnostic and therapeutic interventions undertaken.